Last reviewed · How we verify

Topical IBU three times daily

Pfizer · Phase 3 active Small molecule

Topical IBU three times daily is a NSAID Small molecule drug developed by Pfizer. It is currently in Phase 3 development for Relief of pain and inflammation in musculoskeletal and joint disorders.

Topical IBU works by reducing pain and inflammation at the site of application.

Topical IBU works by reducing pain and inflammation at the site of application. Used for Relief of pain and inflammation in musculoskeletal and joint disorders.

At a glance

Generic nameTopical IBU three times daily
SponsorPfizer
Drug classNSAID
TargetCOX-1 and COX-2
ModalitySmall molecule
Therapeutic areaPain management
PhasePhase 3

Mechanism of action

It does this by inhibiting the production of prostaglandins, which are chemicals that cause pain and inflammation. This is achieved through the inhibition of cyclooxygenase enzymes, specifically COX-1 and COX-2.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Topical IBU three times daily

What is Topical IBU three times daily?

Topical IBU three times daily is a NSAID drug developed by Pfizer, indicated for Relief of pain and inflammation in musculoskeletal and joint disorders.

How does Topical IBU three times daily work?

Topical IBU works by reducing pain and inflammation at the site of application.

What is Topical IBU three times daily used for?

Topical IBU three times daily is indicated for Relief of pain and inflammation in musculoskeletal and joint disorders.

Who makes Topical IBU three times daily?

Topical IBU three times daily is developed by Pfizer (see full Pfizer pipeline at /company/pfizer).

What drug class is Topical IBU three times daily in?

Topical IBU three times daily belongs to the NSAID class. See all NSAID drugs at /class/nsaid.

What development phase is Topical IBU three times daily in?

Topical IBU three times daily is in Phase 3.

What are the side effects of Topical IBU three times daily?

Common side effects of Topical IBU three times daily include Gastrointestinal upset, Skin irritation.

What does Topical IBU three times daily target?

Topical IBU three times daily targets COX-1 and COX-2 and is a NSAID.

Related